Recent progress of clinical trials in urologic oncology

Shiro Hinotsu

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

In Japan, after New Good Clinical Practice put into operation, it has became improved the environment of conducting clinical trials for new drug approval. Clinical trial supporting system, such as data management system, have been developing. It is important to introduce the know-how into clinical trials that is not for new drug approval. Randomized controlled clinical trials are considered to be high evidence level study design. In some fields, it is very difficult and is not appropriate to conduct randomized controlled trials. In such fields, it is appropriate for well designed descriptive studies. And it should be accepted as high evidence level study for well designed descriptive studies. For cytostatic antineoplastic agents, it should be introduced new evaluation method such as randomized discontinuation design.

Original languageEnglish
Pages (from-to)188-192
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume33
Issue number2
Publication statusPublished - Feb 2006

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Recent progress of clinical trials in urologic oncology'. Together they form a unique fingerprint.

Cite this